FIRST-IN-HUMAN · ROUND OPENING SOON

Back a gentler future for varicose vein treatment.

Veinsound is now in First-in-Human trials. Non-thermal focused ultrasound — no incision, no heat — moving from promise to proof. An investment round is opening, and this is the moment to get on
the list.

See how it works

First patients treated · 2026

BACKED BY

INSERM U1032 · BPI France · advisory board of vascular surgeons & phlebologists

THE MOMENT

Few energy-based venous technologies ever reach the human stage. Ours just did.

Backing a medtech at the exact point it moves from preclinical promise to clinical proof is rare — and time-bound. The upcoming round on a platform dedicated to medical and life-science ventures is that entry point.

THE TECHNOLOGY

Focused ultrasound. No
scalpel, no heat.

Veinsound's device lets phlebologists treat superficial venous disease
in-office. High-intensity focused ultrasound excites micro-bubbles inside
the vein until they collapse — cavitation that scours and closes the vein
wall.

Guided in real time by AI-assisted duplex ultrasound. No injections, no thermal
energy, no downtime.

Fast

A single in-office session, minutes not hours.

Painless

No injections and no incision for the patient.

Safe

Non-thermal energy, guided by live imaging.

In-office

No operating theatre, no general anaesthesia.

THE OPPORTUNITY

Invest at the promise-to-proof inflection.

In the coming weeks we'll open a round on a platform dedicated
to medical and life-science ventures. Amounts, timing and the
link are being finalized — our early list hears first.

Clinical validation underway — First-in-Human data generation across 2026.

A large, underserved market with clear clinician pull.

Institutional backing from France 2030, BPI and INSERM.

Be first when the round opens.

Leave your details and we'll reach out with the round terms, timing and the platform link before it goes public.

This is not an offer to invest. We'll only use your details to contact you about the upcoming round.